NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma

Interventions: Drug: sunitinib malate

First Posted Date: 2006-10-26

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00392496

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

Diindolylmethane in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy, no Evidence of Disease

Interventions: Drug: oral microencapsulated diindolylmethane

First Posted Date: 2006-10-26

Last Posted Date: 2016-12-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT00392652

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Bevacizumab and Irinotecan to Treat Brain Tumors

Phase 2

Terminated

Conditions: High-Grade Gliomas

Interventions: Biological: Bevacizumab
Drug: Irinotecan hydrochloride

First Posted Date: 2006-10-26

Last Posted Date: 2012-07-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00393094

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Phase 2

Completed

Conditions: Anti-p53 TCR-Gene

Interventions: Biological: anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes
Biological: aldesleukin
Biological: filgrastim
Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2006-10-26

Last Posted Date: 2011-08-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00393029

Locations: 🇺🇸
National Institutes of Health, Bethesda, Maryland, United States

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Erythroid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Refractory Anemia
Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome With Ring Sideroblasts
Acute Megakaryoblastic Leukemia
Myelodysplastic Syndrome With Excess Blasts

Interventions: Drug: Azacitidine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Vorinostat

First Posted Date: 2006-10-26

Last Posted Date: 2025-02-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 135

Registration Number: NCT00392353

Locations: 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States

and more 4 locations

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

Phase 2

Completed

Conditions: Metastatic Cancer
Pain
Prostate Cancer

Interventions: Drug: Tandutinib

First Posted Date: 2006-10-19

Last Posted Date: 2014-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00390468

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Phase 3

Completed

Conditions: Estrogen Receptor Positive
HER2 Positive Breast Carcinoma
HER2/Neu Negative
Progesterone Receptor Positive
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Fulvestrant
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Drug: Lapatinib Ditosylate

First Posted Date: 2006-10-19

Last Posted Date: 2019-12-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 295

Registration Number: NCT00390455

Locations: 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
University of Maryland Shore Medical Center at Easton, Easton, Maryland, United States
🇺🇸
Saint Vincent Healthcare, Billings, Montana, United States

and more 363 locations

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Phase 2

Completed

Conditions: Multiple Endocrine Neoplasia Type 2A
Stage IV Thyroid Gland Medullary Carcinoma AJCC v7
Sporadic Thyroid Gland Medullary Carcinoma
Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
Locally Advanced Thyroid Gland Medullary Carcinoma
Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7
Hereditary Thyroid Gland Medullary Carcinoma
Stage III Thyroid Gland Medullary Carcinoma AJCC v7
Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
Multiple Endocrine Neoplasia Type 2B

Interventions: Drug: Sorafenib Tosylate

First Posted Date: 2006-10-19

Last Posted Date: 2024-02-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00390325

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

3-AP in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: triapine
Other: pharmacological study
Procedure: laboratory biomarker analysis

First Posted Date: 2006-10-19

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00390052

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Cervical Adenocarcinoma
Cervical Adenosquamous Cell Carcinoma
Recurrent Cervical Cancer
Stage IVB Cervical Cancer
Cervical Squamous Cell Carcinoma

Interventions: Drug: sunitinib malate

First Posted Date: 2006-10-19

Last Posted Date: 2015-02-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00389974

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

AI-Powered Research

Premium Access

NATIONAL INSTITUTES OF HEALTH

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Diindolylmethane in Healthy Volunteers

Bevacizumab and Irinotecan to Treat Brain Tumors

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

3-AP in Treating Patients With Advanced or Metastatic Solid Tumors

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery